SGLT-2 inhibitors and their potential in the treatment of diabetes

References

• Centers for Disease Control and Prevention National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011 Atlanta, GA US Department of Health and Human Services, Centers for Disease Control and Prevention 2011 Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf Accessed December 27, 2012
   Google Scholar
• Centers for Disease Control and Prevention Diabetes Report Card 2012 Atlanta, GA Centers for Disease Control and Prevention, US Department of Health and Human Services 2012 Available from: http://www.cdc.gov/diabetes/pubs/pdf/DiabetesReportCard.pdf Accessed December 27, 2012
   Google Scholar
• Basile J A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition Postgrad Med 2011 123 4 38 45 21680987
   PubMed Web of Science ®Google Scholar
• Kruger DF Bode B Spollett GR Understanding GLP-1 analogs and enhancing patients success Diabetes Educ 2010 36 Suppl 3 44S 72S 20736387
   PubMed Web of Science ®Google Scholar
• Stark Casagrande S Fradkin JE Saydah SH Rust KF Cowie CC The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010 Diabetes Care Epub 2 15 2013
   Web of Science ®Google Scholar
• Marsenic O Glucose control by the kidney: an emerging target in diabetes Am J Kidney Dis 2009 53 5 875 883 19324482
   PubMed Web of Science ®Google Scholar
• Idris I Donnelly R Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug Diabetes Obes Metab 2009 11 2 79 88 19125776
   PubMed Web of Science ®Google Scholar
• Foote C Perkovic V Neal B Effects of SGLT2 inhibitors on cardiovascular outcomes Diab Vasc Dis Res 2012 9 2 117 123 22381403
   PubMed Web of Science ®Google Scholar
• Vallaeys L Van Biervliet S De Bruyn G Congenital glucose-galactose malabsorption: a novel deletion within the SLC5A1 gene Eur J Pediatr 2013 172 3 409 411 22843301
   PubMed Web of Science ®Google Scholar
• Francis J Geller D Glucosuria Primary Renal Florian Lang Encyclopedia of Molecular Mechanisms of Disease New York Springer-Verlag GmbH Berlin Heidelberg 2009 719 721
   Google Scholar
• Canagliflozin [package insert] Titusville, NJ Janssen Pharmaceuticals, Inc 2013
   Google Scholar
• Song J Dapagliflozin: An emerging treatment option for type 2 diabetes mellitus Formulary [serial on the Internet] 10 2011 46 412 431 http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/dapagliflozin-emerging-treatment-option-type-2 Accessed May 21, 2013
   Google Scholar
• Burki T FDA rejects novel diabetes drug over safety fears Lancet 2012 379 9815 507 22334883
   PubMed Web of Science ®Google Scholar
• Ptaszynska A Johnsson K Apanovitch A Sugg J Parikh S List J Safety of Dapagliflozin in Clinical Trials for T2DM Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Leiter L Cefalu W de Bruin T Gause-Nilsson I Sugg J Parikh S Efficacy and Safety of Dapagliflozin for Type 2 Diabetes Mellitus Patients with a History of Cardiovascular Disease Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Dapagliflozin [summary of product characteristics] Middlesex, United Kingdom Bristol-Myers Squibb/AstraZeneca 2013
   Google Scholar
• List JF Woo V Morales E Tang W Fiedorek FT Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 2009 32 4 650 657 19114612
   PubMed Web of Science ®Google Scholar
• Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 2010 33 10 2217 2224 20566676
   PubMed Web of Science ®Google Scholar
• Woo V Tang W Salsali A List J Long-term Efficacy of Dapagliflozin Monotherapy in Patients with Type 2 Diabetes Mellitus Presented at IDF World Diabetes Congress December 4–8, 2011 Dubai, United Arab Emirates
   Google Scholar
• Nauck M Del Prato S Rohwedder K Theuerkauf A Langkilde A Parikh S Long-tern Efficacy and Safety of Dapagliflozin vs Glipizide Added to Metformin in Patients with Inadequately Controlled T2DM Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barcelona, Spain
   Google Scholar
• Nauck M Del Prato S Rohwedder K Theuerkauf A Langkilde A Parikh S Long-term Efficacy and Safety of Add-on Dapagliflozin vs Add-on Glipizide in Patients with T2DM Inadequately Controlled with Metformin: 2-year Results Presented at 71st American Diabetes Association Scientific Sessions June 24–28, 2011 San Diego, CA, USA
   Google Scholar
• Del Prato S Nauck M Rohwedder K Theuerkauf A Langkilde A Parikh S Long-term Efficacy and Safety of Add-on Dapagliflozin vs Add-on Glipizide in Patients with T2DM Inadequately Controlled with Metformin: 2-year Results Presented at 47th EASD Annual Meeting September 12–16, 2011 Lisbon, Portugal
   Google Scholar
• Nauck MA Del Prato S Meier JJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 9 2015 2022 21816980
   PubMed Web of Science ®Google Scholar
• Bailey C Gross J Hennicken D Iqbal N Mansfield T List J Long-term Efficacy of Dapagliflozin as Add-on to Metformin in T2DM Inadequately Controlled with Metformin Alone Presented at 71st American Diabetes Association Scientific Sessions June 24–28, 2011 San Diego, CA, USA
   Google Scholar
• Bailey C Gross J Hennicken D Iqbal N Mansfield T List J Long-term Efficacy of Dapagliflozin as Add-on to Metformin in T2DM Inadequately Controlled with Metformin Alone Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barcelona, Spain
   Google Scholar
• Strojek K Yoon KH Hruba V Elze M Langkilde AM Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 2011 13 10 928 938 21672123
   PubMed Web of Science ®Google Scholar
• Rosenstock J Vico M Wei L Salsali A List J Dapagliflozin Added-On to Pioglitazone Reduces HbA1c and Mitigates Weight Gain with low Incidence of Hypoglycemia in Type 2 Diabetes Presented at 71st American Diabetes Association Scientific Sessions June 24–28, 2011 San Diego, CA, USA
   Google Scholar
• Vico M Wei L Salsali A List J Rosenstock J Dapagliflozin Added-on to Pioglitazone is Effective in Improving Glycaemic Control and Attenuates Weight Gain Without Increasing Hypoglycemia in Patients with Type 2 Diabetes Presented at 47th EASD Annual Meeting September 12–16, 2011 Lisbon, Portugal
   Google Scholar
• Rosenstock J Vico M Wei L Salsali A List JF Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 2012 35 7 1473 1478 22446170
   PubMed Web of Science ®Google Scholar
• Wilding J Woo V Soler N Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 2012 156 6 405 415 22431673
   PubMed Web of Science ®Google Scholar
• Woo V Wilding J Rohwedder K Sugg J Parikh S Long-term Effectiveness of Dapagliflozin Over 104 Weeks in Patients with T2DM Inadequately Controlled with Insulin Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barcelona, Spain
   Google Scholar
• Wilding J Woo V Rohwedder K Sugg J Parikh S Long-Term Effectiveness of Dapagliflozin Over 104 Weeks in Patients with Type 2 Diabetes Poorly Controlled with Insulin Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• FDAgov [homepage on the Internet] Silver Spring, MD US Food and Drug Administration Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm Accessed May 21, 2013
   Google Scholar
• Jnj.com [homepage on the Internet] Raritan, NJ Johnson and Johnson Available from: http://www.jnj.com/connect/news/all/fda-advisory-committee-recommends-approval-of-canagliflozin-for-treatment-of-adults-with-type-2-diabetes Accessed May 21, 2013
   Google Scholar
• Stenlof K Cefalu W Tong C Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemic control in subjects with type 2 diabetes inadequately controlled with diet and exercise Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Polidori D Law G Alba M Ferrannini E Treatment with Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, for 26 Weeks Improves Indices of Beta-cell function Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Cefalu W Leiter L Niskanen L Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Compared With Glimepiride in Patients with Type 2 Diabetes on Background Metformin Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Niskanen L Cefalu W Leiter L Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Niskanen L Cefalu W Leiter L Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barcelona, Spain
   Google Scholar
• Wilding J Mathieu C Vercruysse F Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Wilding J Mathieu C Deng L Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Gross J Schernthaner G Fu M Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Compared with Sitagliptin in Patients with Type 2 Diabetes On Metformin Plus Sulfonylurea Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Schernthaner G Gross J Fu M Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulphonylurea Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barcelona, Spain
   Google Scholar
• Polidori D Vercruysse F Ferrannini E Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves indices of beta cell function in patients with type 2 diabetes on metformin plus sulphonylurea Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Forst T Guthrie R Goldenberg R Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes on Metformin and Pioglitazone Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barcelona, Spain
   Google Scholar
• Matthews D Fulcher G Perkovic V Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy with or without oral agents in type 2 diabetes Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Newsroom.lilly.com [homepage on the Internet] Indianapolis, IN Eli Lilly and Company; Boehringer Ingelheim Available from: http://newsroom.lilly.com/releasedetail.cfm?releaseid=731715 Accessed May 21, 2013
   Google Scholar
• Ferrannini E Seman L Seewaldt-Becker E Hantel S Pinnetti S Worle H The Potent and Highly Selective Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor BI 10773 is Safe and Efficacious in Patients with Type 2 Diabetes Mellitus (T2DM) Presented at 46th EASD Annual Meeting September 20–24, 2010 Stockholm, Sweden
   Google Scholar
• Woerle H Ferrannini E Berk A Hantel S Pinnetti S Broedl U Safety and Efficacy of Empagliflozin as Monotherapy or Add-On to Metformin in a 78-Week Open-Label Extension Study in Patients with Type 2 Diabetes Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Rosenstock J Jelaska A Seman L Pinnetti S Hantel S Woerle H Efficacy and Safety of BI 10773 (Empagliflozin), a New Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, in Type 2 Diabetes Inadequately Controlled on Metformin Presented at 71st American Diabetes Association Scientific Sessions June 24–28, 2011 San Diego, CA, USA
   Google Scholar
• Kurosaki E Ogasawara H Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data Pharmacol Ther 7 2013 139 1 51 59 23563279
   PubMed Web of Science ®Google Scholar
• Kashiwagi A Shiga T Akiyama N Ipragliflozin reduced HbA1c and body weight in Japanese type 2 diabetes patients who have inadequate glycaemic control on sulfonylurea or pioglitazone alone Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Freiman J Ye G Ogbaa I LX4211, a dual SGLT1/SGLT2 inhibitor shows a favourable gastrointestinal and genitourinary safety profile in type 2 diabetes mellitus patients and healthy subjects Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Lexicon-genetics.com [homepage on the Internet] The Woodlands, TX Lexicon Pharmaceuticals Available from: http://www.lexicon-genetics.com/pipeline/lx4211.html Accessed May 21, 2013
   Google Scholar
• Chugai-pharm.com [homepage on the Internet] Chuo-ku, Tokyo Chugai Pharma USA Available from: http://www.chugai-pharm.co.jp/hc/ss/english/ir/reports_downloads/pipeline.html Accessed May 21, 2013
   Google Scholar
• Ikeda S Takano Y Cynshi O A novel and selective SGLT2 inhibitor, tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Taisho-holdings.co.jp/en [homepage on the Internet] Toshima-ku, Tokyo Taisho Pharmaceutical Available from: http://www.taisho-holdings.co.jp/en/release/2012/2012113001-e.pdf Accessed May 21, 2013
   Google Scholar
• Pfizer.newshq.businesswire.com [homepage on the Internet] New York, NY Pfizer Available from: http://pfizer.newshq.businesswire.com/press-release/merck-co-inc-and-pfizer-enter-worldwide-collaboration-agreement-develop-and-commercial Accessed May 21, 2013
   Google Scholar
• Chao EC Henry RR SGLT2 inhibition-a novel strategy for diabetes treatment Nat Rev Drug Discov 7 2010 9 7 551 559 20508640
   PubMed Web of Science ®Google Scholar
• Bailey C Iqbal N T’joen C List J Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range Diabetes Obes Metab 2012 14 10 951 959 22776824
   PubMed Web of Science ®Google Scholar
• Kanbay M Segal M Afsar B Kang DH Rodriguez-Iturbe B Johnson RJ The role of uric acid in the pathogenesis of human cardiovascular disease Heart 2013 99 11 759 766 23343689
   PubMed Web of Science ®Google Scholar
• Zhang L Feng Y List J Kasichayanula S Pfister M Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight Diabetes Obes Metab 2010 12 6 510 516 20518806
   PubMed Web of Science ®Google Scholar
• Toubro S Cefalu W Xie J Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Toubro S Cefalu W Xie J Canagliflozin reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barcelona, Spain
   Google Scholar
• Bolinder J Ljunggren O Kullberg J Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 2012 97 3 1020 1031 22238392
   PubMed Web of Science ®Google Scholar
• Hach T Lambers Heerspink H Pfarr E Lund S Ley L Broedl U The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Empagliflozin Lowers Blood Pressure Independent of Weight or HbA1c Changes [poster 65] Proceedings of the 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barcelona, Spain
   Google Scholar
• Abdul-Ghani MA Norton L DeFronzo RA Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus Curr Diab Rep 2012 12 3 230 238 22528597
   PubMed Web of Science ®Google Scholar
• Damkjær M Isaksson GL Stubbe J Jensen BL Assersen K Bie P Renal renin secretion as regulator of body fluid homeostasis Pflugers Arch 2013 465 1 153 165 23096366
   PubMed Web of Science ®Google Scholar
• Thomson S Rieg T Miracle C Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat Am J Physiol Regul Integr Comp Physiol 2012 302 1 R75 R83 21940401
   PubMed Web of Science ®Google Scholar
• Woo V Hardy E Ptaszynska A Parikh S Effects of the SGLT2 Inhibitor Dapagliflozin Beyond Glucose Reduction in Patients with Type 2 Diabetes mellitus Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barcelona, Spain
   Google Scholar
• Hardy E Rohwedder K Hruba V Dapagliflozin, an AGLT2 Inhibitor, reduces Serum Levels of Uric Acid in patients with Type 2 Diabetes Presented at 71st American Diabetes Association Scientific Sessions June 24–28, 2011 San Diego, CA, USA
   Google Scholar
• Mount DB Kwon CY Zandi-Nejad K Renal urate transport Rheum Dis Clin North Am 2006 32 2 313 331 vi 16716882
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Liu X Pe Benito M The influence of kidney function on dapagliflozin exposure, metabolism, and efficacy in healthy subjects and in patients with type 2 diabetes mellitus Br J Clin Pharmacol Epub 12 4 2012
   Web of Science ®Google Scholar
• Yale JF Bakris G Xi L Figueroa K Wajs E Usiskin K Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor, Improves Glycemia and is Well Tolerated in Type 2 Diabetes Mellitus (T2DM) Subjects With Moderate Renal Impairment Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Bakris G Yale JF Xi L Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) and Moderate Renal Impairment Presented at ASN Kidney Week October 30–November 4, 2012 San Diego, CA, USA
   Google Scholar
• Yale JF Bakris G Wajs E Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemic control and is well tolerated in type 2 diabetes subjects with moderate renal impairment Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Woo V Davies M de Zeeuw D Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes Mellitus and Moderate Renal Impairment Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy) November 8–11, 2012 Barce-lona, Spain
   Google Scholar
• Kohan D Fioretto P List J Tang W Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment Presented at ASN Kidney Week November 10–13, 2011 Philadelphia, PA, USA
   Google Scholar
• Ptaszynska A Chalamandaris AG Sugg J Johnsson K Parikh S List J Effect of Dapagliflozin on Renal Function [poster 1098-P] Proceedings of the 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Kasichayanula S Liu X Pe Benito M LaCreta F Boulton D Influence of Renal Function on Dapagliflozin Pharmacodynamics in Patients with Type 2 Diabetes Mellitus Presented at ASN Kidney Week November 10–13, 2011 Philadelphia, PA, USA
   Google Scholar
• van Lierop AH Hamdy NA van der Meer RW Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus Eur J Endocrinol 2012 166 4 711 716 22267280
   PubMed Web of Science ®Google Scholar
• Bode B Stenlof K Sullivan D Fung A Usiskin K Meininger G Efficacy and safety of canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor (SGLT2), in older subjects with type 2 diabetes mellitus Presented at 48th EASD Annual Meeting October 1–5, 2012 Berlin, Germany
   Google Scholar
• Dormandy J Bhattacharya M van Troostenburg de Bruyn AR PROactive investigators Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive Drug Saf 2009 32 3 187 202 19338377
   PubMed Web of Science ®Google Scholar
• Cefalu W Leiter L de Bruin T Gause-Nilsson I Sugg J Parikh S Dapagliflozin Treatment for Type 2 Diabetes Mellitus patietns with Comorbid Cardiovascular Disease and Hypertension Presented at 72nd American Diabetes Association Scientific Sessions June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar